Italia Markets close in 8 hrs 6 mins

Cosmo Pharmaceuticals N.V. (0RGI.L)

LSE - LSE Prezzo differito. Valuta in CHF.
Aggiungi a watchlist
71,200,00 (0,00%)
In data: 03:10PM BST. Mercato aperto.

Cosmo Pharmaceuticals N.V.

Riverside II
Sir John Rogerson’s Quay
Dublin 2
353 1 817 0370

Impiegati a tempo pieno325

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Alessandro E. Della Cha LL.MExecutive Chairman576,29kN/D1963
Mr. Niall DonnellyExecutive Director & CFON/DN/D1972
Mr. Giovanni Di NapoliChief Executive Officer & DirectorN/DN/D1974
Mr. Mauro Severino AjaniFounder & Non-Executive Director379,88kN/D1955
Mr. Marco LecchiChief Operating OfficerN/DN/D1964
Mr. Davide MalavasiQualified Person & Technical DirectorN/DN/D1973
Mr. Luigi LongoChief Scientific OfficerN/DN/D1979
Ms. Hazel WinchesterHead of Investor RelationsN/DN/D1971
Mr. Biagio ViganoChief People OfficerN/DN/D1974
Mr. Roberto VillaChief Manufacturing OfficerN/DN/D1943
Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in CHF.


Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, a submucosal injectable composition to allow endoscopists with a faster and less risky excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Relafalk, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers' diarrhoea; and Byfavo, an intravenous benzodiazepine sedative/anesthetic. It is also developing Breezula, a novel androgen receptor inhibitor, which is in Phase III trials and targets androgen receptors in the scalp; Rifamycin SV MMX – IBS-D, a formulation that is in Phase III clinical trial to treat colonic infections and irritable bowel syndrome with diarrhoea; CB-03-10, an oral androgen receptor antagonist, which is in Phase I clinical trial for treatment solid tumors; CB-01-33 that is in preclinical studies for the treatment of bile acid diarrhea; and CB-01-35, an enema solution, which is in Phase II clinical trial for the treatment of distal ulcerative colitis and proctitis. The company has development, distribution, and licensing agreements with Bausch Health, Ferring, China Medical System Holdings Limited, Medtronic, RedHill Biopharma Ltd., Sun Pharmaceutical Industries Ltd., 3SBio, InfectoPharm, and Hyphens Pharma International Limited. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.

Governance aziendale

L'ISS Governance QualityScore di Cosmo Pharmaceuticals N.V. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.